Pediatr. praxi 2018; 19(2): 91-96 | DOI: 10.36290/ped.2018.019

Current possibilities of biologic therapy in paediatric rheumatology

MUDr. Hana Malcová, Ph.D.1, MUDr. Rudolf Horváth, Ph.D.1, prof. MUDr. Pavla Doležalová, CSc.2
1 Oddělení revmatologie dětí a dospělých, Fakultní nemocnice v Motole, Praha
Centrum dětské revmatologie a autoinflamatorních onemocnění Všeobecné fakultní nemocnice v Praze,
2 Klinika dětského a dorostového lékařství, Praha

Therapy of paediatric rheumatic diseases has radically changed over the past twenty years with introduction of biologic drugs. Thesenew drugs represent a significant advance in targeted and effective treatment especially for children with juvenile idiopathic arthritis.However, biologics are used off-label in other serious systemic inflammatory diseases, such as systemic lupus erythematosus,juvenile dermatomyositis, systemic vasculitis, and autoinflammatory diseases. With the modern treatment, most our patients reachremission and they are thus able to lead a normal life without any limitation. According to the mechanism of action, we can dividebiologic drugs into those that interfere with proinflammatory cytokines and those that block the function of T or B lymphocytes.This article deals with selected groups of biologics, their indication, side effects and some problems concerning their use.

Keywords: biologic therapy, paediatric rheumatology, juvenile idiopathic arthritis (JIA), TNFα inhibitors, IL-1 blockers, IL-6 blockers

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malcová H, Horváth R, Doležalová P. Current possibilities of biologic therapy in paediatric rheumatology. Pediatr. praxi. 2018;19(2):91-96. doi: 10.36290/ped.2018.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-482. Go to original source... Go to PubMed...
    2. Vencovský J a výbor České revmatologické společnosti. Bezpečnost biologické léčby - Doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146-160.
    3. De La Forest Divonne M, Gottenberg JE, Salliot C. Dafety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017; 84(2): 133-140. Go to original source... Go to PubMed...
    4. Kostjukovits S, Kalliokoski L, Antila K, et al. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr. 2015; 174: 707-714. Go to original source... Go to PubMed...
    5. Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: A prospective, open label, dose excalation study. Arthritis Rheum. 2012; 64: 908-913. Go to original source... Go to PubMed...
    6. Taddio A, Zennaro F, Pastore S, et al. An Update on the Pathogenesis and Treatment of Chronic Recurrent Multifocal Osteomyelitis in Children. Paediatr Drugs. 2017; 19(3): 165-172. Go to original source... Go to PubMed...
    7. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of antitumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008; 20(4): 431-435. Go to original source... Go to PubMed...
    8. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017; 376(17): 1637-1646. Go to original source... Go to PubMed...
    9. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017; 76(2): 329-340. Go to original source... Go to PubMed...
    10. Eleftheriou D, Brogan PA. Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol Online J. 2016; 14(1): 26. Go to original source... Go to PubMed...
    11. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017; May 15. Go to original source...
    12. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016; 14(1): 27. Go to original source... Go to PubMed...
    13. Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014; 22(2): 90-95. Go to original source... Go to PubMed...
    14. Ruperto N, Lovell D, Cuttica R, et al. A randomised, placebo-controlled trial of infliximab plus methotrexat for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56(9): 3096-3106. Go to original source... Go to PubMed...
    15. Lamot L, Bukovac LT, Vidovic M, et al. The, head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011; 29(1): 131-139. Go to PubMed...
    16. Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Intern. 2015; 35(5): 777-785. Go to original source... Go to PubMed...
    17. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child. 2014; 99(1): 74-83. Go to original source... Go to PubMed...
    18. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017; 135(17): 927-999. Go to original source... Go to PubMed...
    19. Vallet H, Seve P, Biard L, et al. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2016; 68(6): 1522-1530. Go to original source... Go to PubMed...
    20. De Benedetti F. Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med. 2013; 368(13): 1256-1257. Go to original source...
    21. Gerd Horneff. Biologic-Associated Infections in Pediatric Rheumatology. Current Rheumatology Reports. 2015; 17: 66. Go to original source... Go to PubMed...
    22. Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015; 27(5): 505-510. Go to original source... Go to PubMed...
    23. Grimwood C, Despert V, Jeru I, et al. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford) 2015; 54: 1749-1751. Go to original source... Go to PubMed...
    24. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014; 65: 223-244. Go to original source... Go to PubMed...
    25. Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017; 69(4): 854-862. Go to original source... Go to PubMed...
    26. Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 Inhibition in Behçet's disease. Isr Med Assoc J. 2016; 18(3-4): 171-176. Go to PubMed...
    27. Sen ES, Clarke SL, Ramanan AV. Macrophage Activation Syndrome. Indian J Pediatr. 2016; 83(3): 248-253. Go to original source... Go to PubMed...
    28. Tremoulet AH, Jain S, Kim S, et al. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016; 48: 70-75. Go to original source... Go to PubMed...
    29. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013; 65(10): 1551-1563. Go to original source... Go to PubMed...
    30. Quartier P, Allantaz F, Cimaz R, et al. Extended report: a multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011; 70: 747-754. Go to original source... Go to PubMed...
    31. Pardeo M, Marafon P, Insalaco A, et al. Anakinra in systemic juvenile idiopathic arthritis: A single-center experience. J Rheumatol 2015; 42: 1523-1527. Go to original source... Go to PubMed...
    32. DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012; 64(7): 1001-1010. Go to original source... Go to PubMed...
    33. Kuemmerle-Deschner JB, Hofer F, Endres T, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016; 55(4): 689-696. Go to original source... Go to PubMed...
    34. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367(25): 2396-2406. Go to original source... Go to PubMed...
    35. Wulffraat NM. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015; 14(12): 1961-1967. Go to original source... Go to PubMed...
    36. Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017; 76(1): 173-178. Go to original source... Go to PubMed...
    37. Arostegui JI, Anton J, Calvo I, et al. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017; 69(8): 1679-1688. Go to original source... Go to PubMed...
    38. Laskari K, Boura P, Dalekos GN, et al. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. J Rheumatol. 2017; 44(1): 102-109. Go to original source... Go to PubMed...
    39. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenilie idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391. Go to original source... Go to PubMed...
    40. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010; 62(6): 821-825. Go to original source... Go to PubMed...
    41. Birolo C, Zannin ME, Arsenyeva S, et al. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis. J Rheumatol. 2016; 43(11): 2068-2073. Go to original source... Go to PubMed...
    42. Tambralli A, Beukelman T, Cron RQ, et al. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015; 42(3): 541-546. Go to original source... Go to PubMed...
    43. Abinun M. An overview of infectious complications in children on new biologic response-modifying agents. Pediatric Health 2010; 4: 509-517. Go to original source...
    44. Klotsche J, Niewerth M, Haas JP, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2016; 75: 855-861. Go to original source... Go to PubMed...
    45. Tarkiainen M, Tynjälä P, Vähäsalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2015; 54(7): 1170-1176. Go to original source... Go to PubMed...
    46. Calzada-Hernández J, Anton-López J, Bou-Torrent R, et al. Tuberculosis in pediatric patients treated with anti-TNF? drugs: a cohort study. Pediatr Rheumatol 2015; 13: 54. Go to original source... Go to PubMed...
    47. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012; 64: 1263-1271. Go to original source... Go to PubMed...
    48. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76: 1093-1101. Go to original source... Go to PubMed...
    49. Waldstrom H, Frisell T, et al. Malignant neoplasm in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. JAMA Intern Med. 2017; 177(11): 1605-1612. Go to original source... Go to PubMed...
    50. Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int 2015; 35: 661-668. Go to original source... Go to PubMed...
    51. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63(7): 929-936. Go to original source... Go to PubMed...
    52. Kearsley-Fleet L, et al. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford). 2016; 55(9): 1556-1565. Go to original source... Go to PubMed...
    53. Glerup M, Herlin T, Twilt M. Clinical Outcome and Long-term Remission in JIA. Curr Rheumatol Rep. 2017; 19(12): 75. Go to original source... Go to PubMed...
    54. Simonini G, Ferrara G, Pontikaki I, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: Clinical and laboratory correlates of remission duration. Arthritis Care Res (Hoboken). 2017 Oct 3. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.